Suchergebnisse
Filter
Format
Medientyp
Sprache
Weitere Sprachen
Jahre
120661 Ergebnisse
Sortierung:
MS und Schwangerschaft
In: Neurotransmitter, Band 29, Heft 7-8, S. 46-46
ISSN: 2196-6397
Mein erwachsenes Kind hat MS: Empowerment für Angehörige von MS-Erkrankten
Familienplanung mit MS
In: Neurotransmitter, Band 34, Heft 5, S. 51-51
ISSN: 2196-6397
Therapiemanagement bei MS
In: Neurotransmitter, Band 33, Heft 3, S. 45-45
ISSN: 2196-6397
Langzeitwirksamkeit bei MS
In: Neurotransmitter, Band 32, Heft 5, S. 60-61
ISSN: 2196-6397
MS — Nicht nur Patient sein
In: Neurotransmitter, Band 29, Heft 2, S. 49-49
ISSN: 2196-6397
MS in Deutschland
In: Neurotransmitter, Band 27, Heft S1, S. 45-45
ISSN: 2196-6397
MS-Förderprogramm
In: NeuroTransmitter, Band 24, Heft 2, S. 60-60
Nicht der MS hinterherlaufen
In: Neurotransmitter, Band 26, Heft 5, S. 49-49
ISSN: 2196-6397
Ms. Carol
In: Affilia: journal of women and social work, Band 12, Heft 4, S. 486-487
ISSN: 1552-3020
Targeting human urinary metabolome by LC-MS/MS: a review
Urine is a biological matrix that contains hundreds of metabolic end products which constitute the urinary metabolome. The development and advances on LC-MS/MS have revolutionized the analytical study of biomolecules by enabling their accurate identification and quantification in an unprecedented manner. Nowadays, LC-MS/MS is helping to unveil the complexity of urine metabolome, and the results obtained have multiple biomedical applications. This review focuses on the targeted LC-MS/MS analysis of the urine metabolome. In the first part, we describe general considerations (from sample collection to quantitation) required for a proper targeted metabolic analysis. In the second part, we address the urinary analysis and recent applications of four relevant families: amino acids, catecholamines, lipids and steroids. ; J Rodríguez-Morató acknowledges funding from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 712949 (TECNIOspring PLUS) and from the Agency for Business Competitiveness of the Government of Catalonia. Spanish Health National System is acknowledged for O J Pozo contract (CPII16/00027). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
BASE